Maria Blasi

Dr. Maria Blasi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Nature
Verified
Journal Article
Closed access
PDF file
FVFilippo Veglia
Filippo Veglia
VTVladimir A. Tyurin
Vladimir A. Tyurin
MBMaria Blasi
Maria Blasi
ALAlessandra De Leo
Alessandra De Leo
AKAndrew V. Kossenkov
Andrew V. Kossenkov
DGDmitry Gabrilovich
Dmitry Gabrilovich

4 July 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
TTTatianna Travieso
Tatianna Travieso
JLJenny Li
Jenny Li
SMSneha Mahesh
Sneha Mahesh
JMJuliana Da Fonzeca Redenze E. Mello
Juliana Da Fonzeca Redenze E. Mello
MBMaria Blasi
Maria Blasi
Vaccines represent the single most cost-efficient and equitable way to combat and eradicate infectious diseases. While traditional licensed vaccines consist of either inactivated/attenuated versions of the entire pathogen or subunits of it, most novel experimental vaccines against emerging infectious diseases employ nucleic acids to produce the antigen of interest directly in vivo. These include DNA plasmid vaccines, mRNA vaccines, and recombinant viral vectors. The advantages of using nucleic acid vaccines include their ability to induce durable immune responses, high vaccine stability, and ease of large-scale manufacturing. In this review, we present an overview of pre-clinical and clinical data on recombinant viral vector vaccines and discuss the advantages and limitations of the different viral vector platforms.

14 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
FVFilippo Veglia
Filippo Veglia
VTVladimir A. Tyurin
Vladimir A. Tyurin
DMDariush Mohammadyani
Dariush Mohammadyani
MBMaria Blasi
Maria Blasi
EDElizabeth K. Duperret
Elizabeth K. Duperret
DGDmitry Gabrilovich
Dmitry Gabrilovich
Cross-presentation is a critical function of dendritic cells (DCs) required for induction of antitumor immune responses and success of cancer immunotherapy. It is established that tumor-associated DCs are defective in their ability to cross-present antigens. However, the mechanisms driving these defects are still unknown. We find that impaired cross-presentation in DCs is largely associated with defect in trafficking of peptide–MHC class I (pMHC) complexes to the cell surface. DCs in tumor-bearing hosts accumulate lipid bodies (LB) containing electrophilic oxidatively truncated (ox-tr) lipids. These ox-tr-LB, but not LB present in control DCs, covalently bind to chaperone heat shock protein 70. This interaction prevents the translocation of pMHC to cell surface by causing the accumulation of pMHC inside late endosomes/lysosomes. As a result, tumor-associated DCs are no longer able to stimulate adequate CD8 T cells responses. In conclusion, this study demonstrates a mechanism regulating cross-presentation in cancer and suggests potential therapeutic avenues.

19 November 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
COClaire E. Otero
Claire E. Otero
SLStephanie N. Langel
Stephanie N. Langel
MBMaria Blasi
Maria Blasi
SPSallie Permar
Sallie Permar
Rotavirus (RV) vaccine efficacy is significantly reduced in lower- and middle-income countries (LMICs) compared to high-income countries. This review summarizes current research into the mechanisms behind this phenomenon, with a particular focus on the evidence that maternal antibody (matAb) interference is a contributing factor to this disparity. All RV vaccines currently in use are orally administered, live-attenuated virus vaccines that replicate in the infant gut, which leaves their efficacy potentially impacted by both placentally transferred immunoglobulin G (IgG) and mucosal IgA Abs conferred via breast milk. Observational studies of cohorts in LMICs demonstrated an inverse correlation between matAb titers, both in serum and breast milk, and infant responses to RV vaccination. However, a causal link between maternal humoral immunity and reduced RV vaccine efficacy in infants has yet to be definitively established, partially due to limitations in current animal models of RV disease. The characteristics of Abs mediating interference and the mechanism(s) involved have yet to be determined, and these may differ from mechanisms of matAb interference for parenterally administered vaccines due to the contribution of mucosal immunity conferred via breast milk. Increased vaccine doses and later age of vaccine administration have been strategies applied to overcome matAb interference, but these approaches are difficult to safely implement in the setting of RV vaccination in LMICs. Ultimately, the development of relevant animal models of matAb interference is needed to determine what alternative approaches or vaccine designs can safely and effectively overcome matAb interference of infant RV vaccination.

12 July 2024 in Science Immunology
Verified
Journal Article
Closed access
KLKaixin Liang
Kaixin Liang
KBKatherine C. Barnett
Katherine C. Barnett
MHMartin Hsu
Martin Hsu
WCWei-Chun Chou
Wei-Chun Chou
SBSachendra S. Bais
Sachendra S. Bais
JTJenny P.-Y. Ting
Jenny P.-Y. Ting
Virus-induced cell death is a key contributor to COVID-19 pathology. Cell death induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well studied in myeloid cells but less in its primary host cell type, angiotensin-converting enzyme 2 (ACE2)–expressing human airway epithelia (HAE). SARS-CoV-2 induces apoptosis, necroptosis, and pyroptosis in HAE organotypic cultures. Single-cell and limiting-dilution analysis revealed that necroptosis is the primary cell death event in infected cells, whereas uninfected bystanders undergo apoptosis, and pyroptosis occurs later during infection. Mechanistically, necroptosis is induced by viral Z-RNA binding to Z-DNA–binding protein 1 (ZBP1) in HAE and lung tissues from patients with COVID-19. The Delta (B.1.617.2) variant, which causes more severe disease than Omicron (B1.1.529) in humans, is associated with orders of magnitude–greater Z-RNA/ZBP1 interactions, necroptosis, and disease severity in animal models. Thus, Delta induces robust ZBP1-mediated necroptosis and more disease severity.

23 October 2014 in AIDS
Verified
Journal Article
Closed access
MBMaria Blasi
Maria Blasi
BBBala Balakumaran
Bala Balakumaran
PCPing Chen
Ping Chen
DNDonatella Negri
Donatella Negri
ACAndrea Cara
Andrea Cara
MKMary E. Klotman
Mary E. Klotman
Objectives: Increasing evidence supports the role of the kidney as a reservoir for HIV-1. In-vitro co-cultivation of HIV-infected T cells with renal tubule epithelial (RTE) cells results in virus transfer to the latter, whereas cell-free virus infection is inefficient. We further characterized the fate of HIV-1 after it is internalized in renal epithelial cells. Methods: Primary or immortalized CD4+ cells were infected with a green fluorescent protein (GFP)-expressing replication competent HIV-1. HIV-1 transfer from T cells to RTE cells was carried out in a co-culture system and evaluated by fluorescence-activated cell sorting analysis. HIV-1 integration in renal cells was evaluated by Alu-PCR and the production of infectious particles was assessed by p24-ELISA and TZM-bl assay. HIV-infected renal cells were used as donor cells in a co-culture system to evaluate their ability to transfer the virus back to T cells. Results: Renal cells become productively infected by HIV-1 and multiple copies of HIV-1 can be transferred from infected T cells to renal cells. Two separate cell populations were identified among infected renal cells based on reporter gene GFP expression level (low vs. high), only the high showing sensitivity to azidothymidine and ritonavir. Co-cultivation of HIV-1-infected renal cells with noninfected T cells resulted in HIV-1 transmission to T cells, supporting bidirectional exchange of virus between T cells and kidney-derived cells. Persistent expression and generation of infectious virus in renal cells required HIV integration. Conclusion: These results support the kidney as a potential reservoir where virus is exchanged between interstitial T cells and RTE cells.